The Short Answer
Globus Medical stock (GMED) has a qualitative business verdict that is HALAL and passes the known filing-based financial ratios, but the overall screen remains incomplete. Globus Medical develops spine, orthopedic-trauma, and neurotechnology products.
Medical-device manufacturing is generally permissible at the activity level. The March 31, 2026 filing reports debt/assets of 0.01%, liquidity/assets of 14.69% and receivables-plus-cash/assets of 22.93%; the activity numerator remains qualitative.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
0.718 / 5,439.555
799.288 / 5,439.555
1,247.383 / 5,439.555
5.434 / 759.854
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 0.01%, liquidity/assets is 14.69%, receivables-plus-cash/assets is 22.93% and reported net interest income/expense is 0.72%; activity remains qualitative.
- Financial
- Pass
- Overall
- Incomplete
Known debt, liquidity and receivables-plus-cash ratios are below the examined MSCI limits; this is not an index-membership claim and activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and identifiable liquidity/assets are below the examined Malaysia limits; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Globus Medical develops and manufactures musculoskeletal and neurotechnology products, including spine, orthopedic and neuromodulation devices. The core medical-device activity is generally permissible, but the filing does not provide a universal prohibited-revenue numerator for product or customer end uses.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed; product and clinical-use allocation remains qualitative.
Purification
The filing reports net interest income/expense of $5.434 million; ZakatInvest does not prescribe a fixed scholar-approved purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions from Globus Medical's March 31, 2026 Form 10-Q.
- Interest-bearing debt uses the $0.718 million finance-lease liability; no conventional borrowings are reported and operating leases are excluded.
- Cash is $560.950 million and marketable securities are $238.338 million, comprising short- and long-term corporate and government debt securities; net accounts receivable are $686.433 million.
- First-quarter net sales are $759.854 million and reported net interest income/expense is $5.434 million (0.72% of revenue).
- Medical-device and neurotechnology activity is retained as qualitative analysis; no universal prohibited-revenue numerator is disclosed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Sharia Screening Methodology
Islamic scholars use several criteria to screen stocks:
- Business activity screen: Is the company's primary business halal?
- Debt ratio: Total debt / market cap must be under 33%
- Interest income: Interest income / total revenue must be under 5%
- Haram revenue: Revenue from haram sources must be under 5%
- Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)
Globus Medical's Business Activity
Globus Medical provides:
- Spine implants: Implantable devices and instruments for spinal-fusion and related procedures
- Surgical robotics and enabling technology: Imaging, navigation, and robotic platforms for surgery
- Orthopedic trauma and other: A broadened musculoskeletal portfolio following the NuVasive merger
These are general-purpose healthcare and medical-device businesses — developing implants and surgical technology that treat patients. This is permissible at the activity level.
Concerns to Be Aware Of
1. Minor Interest Income
The filing reports net interest income/expense of $5.434 million, or 0.72% of quarterly revenue. ZakatInvest does not prescribe a fixed scholar-approved purification percentage; Globus does not currently pay a dividend.
2. Regulatory and Integration Risk
The medical-device business depends on reimbursement, regulatory clearances, surgeon-adoption, and the integration of the NuVasive merger. These are business and regulatory considerations rather than Sharia screen concerns.
3. Procedure-Volume Sensitivity
Earnings can be sensitive to elective-procedure volumes and hospital-capital-spending. This is a business-cycle consideration rather than a Sharia screen concern.
Filing-Based Ratios (March 31, 2026)
Using Globus Medical's latest Form 10-Q (USD millions):
- Debt / total assets: 0.01%
- Cash + securities / total assets: 14.69%
- Receivables + cash / total assets: 22.93%
- Reported net interest income/expense / revenue: 0.72%
Methodology Interpretation
These are ZakatInvest calculations from the cited filing, not claims of current index membership or an official scholar ruling:
- FTSE-style: Known financial ratios pass; activity remains qualitative.
- MSCI-style: Known financial ratios pass; this is not an index-membership claim.
- Malaysia-style: Known debt and liquidity ratios pass; this is not an official classification.
Bottom Line
Globus Medical (GMED) has a generally permissible medical-device and neurotechnology business and passes the known filing-based ratios. Because no universal prohibited-revenue numerator is disclosed, the overall result remains incomplete rather than a universal halal certification; consult the methodology you follow.
For Muslim investors seeking medical-device exposure, GMED sits alongside other halal-screened names like Zimmer Biomet (ZBH) and Boston Scientific (BSX).
Want to check if another stock is halal? Use our free screener.
Open Halal Checker →